Therapeutic potential of dithiolethiones for hepatic diseases

Samuel Carroll Brooks, Janie Sue Brooks, Woo Hyung Lee, Myung Gull Lee, Sang Geon Kim

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Comprehensive studies support the notion that oltipraz [4-methyl-5-(2-pyrazynyl)-1,2-dithiole-3-thione] and its congeners exert cancer chemopreventive effects by the prevention, inhibition or reversal of carcinogenic processes. Recently, it was found that dithiolethione compounds had the activities to prevent or treat fibrosis, insulin resistance, and mitochondrial protective effects in the liver by a mechanism involving AMP-activated protein kinase (AMPK) and/or 70-kDa ribosomal protein S6 kinase 1 (S6K1). Moreover, chemical regulation of the AMPK-S6K1 pathway was found to affect Liver X receptor (LXR) activity and lipogenesis, leading to the identification of AMPK and S6K1 as targets for treating hepatic steatosis. These biological activities of dithiolethiones may offer a novel approach to pharmaceutical intervention. This review focuses on the interaction between oltipraz and the AMPK-mTOR-S6K1 pathway, which regulates genes that confer hepatocyte protection from intoxication, disrupted energy metabolism, and inflammation. In terms of therapeutic potential, the findings reviewed here demonstrate a new therapeutic potential for dithiolethiones, which function in a unique manner, and offer the possibility of new treatments for hepatic diseases.

Original languageEnglish
Pages (from-to)31-43
Number of pages13
JournalPharmacology and Therapeutics
Volume124
Issue number1
DOIs
Publication statusPublished - 2009 Oct 1

Fingerprint

Ribosomal Protein S6 Kinases
AMP-Activated Protein Kinases
Liver
70-kDa Ribosomal Protein S6 Kinases
Lipogenesis
Energy Metabolism
Insulin Resistance
Hepatocytes
Fibrosis
Therapeutics
Inflammation
Pharmaceutical Preparations
Genes
Neoplasms
AMP-activated protein kinase kinase
oltipraz

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Brooks, Samuel Carroll ; Brooks, Janie Sue ; Lee, Woo Hyung ; Lee, Myung Gull ; Kim, Sang Geon. / Therapeutic potential of dithiolethiones for hepatic diseases. In: Pharmacology and Therapeutics. 2009 ; Vol. 124, No. 1. pp. 31-43.
@article{2af609c59df44762a7e24379e53d3f0a,
title = "Therapeutic potential of dithiolethiones for hepatic diseases",
abstract = "Comprehensive studies support the notion that oltipraz [4-methyl-5-(2-pyrazynyl)-1,2-dithiole-3-thione] and its congeners exert cancer chemopreventive effects by the prevention, inhibition or reversal of carcinogenic processes. Recently, it was found that dithiolethione compounds had the activities to prevent or treat fibrosis, insulin resistance, and mitochondrial protective effects in the liver by a mechanism involving AMP-activated protein kinase (AMPK) and/or 70-kDa ribosomal protein S6 kinase 1 (S6K1). Moreover, chemical regulation of the AMPK-S6K1 pathway was found to affect Liver X receptor (LXR) activity and lipogenesis, leading to the identification of AMPK and S6K1 as targets for treating hepatic steatosis. These biological activities of dithiolethiones may offer a novel approach to pharmaceutical intervention. This review focuses on the interaction between oltipraz and the AMPK-mTOR-S6K1 pathway, which regulates genes that confer hepatocyte protection from intoxication, disrupted energy metabolism, and inflammation. In terms of therapeutic potential, the findings reviewed here demonstrate a new therapeutic potential for dithiolethiones, which function in a unique manner, and offer the possibility of new treatments for hepatic diseases.",
author = "Brooks, {Samuel Carroll} and Brooks, {Janie Sue} and Lee, {Woo Hyung} and Lee, {Myung Gull} and Kim, {Sang Geon}",
year = "2009",
month = "10",
day = "1",
doi = "10.1016/j.pharmthera.2009.06.006",
language = "English",
volume = "124",
pages = "31--43",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "1",

}

Therapeutic potential of dithiolethiones for hepatic diseases. / Brooks, Samuel Carroll; Brooks, Janie Sue; Lee, Woo Hyung; Lee, Myung Gull; Kim, Sang Geon.

In: Pharmacology and Therapeutics, Vol. 124, No. 1, 01.10.2009, p. 31-43.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Therapeutic potential of dithiolethiones for hepatic diseases

AU - Brooks, Samuel Carroll

AU - Brooks, Janie Sue

AU - Lee, Woo Hyung

AU - Lee, Myung Gull

AU - Kim, Sang Geon

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Comprehensive studies support the notion that oltipraz [4-methyl-5-(2-pyrazynyl)-1,2-dithiole-3-thione] and its congeners exert cancer chemopreventive effects by the prevention, inhibition or reversal of carcinogenic processes. Recently, it was found that dithiolethione compounds had the activities to prevent or treat fibrosis, insulin resistance, and mitochondrial protective effects in the liver by a mechanism involving AMP-activated protein kinase (AMPK) and/or 70-kDa ribosomal protein S6 kinase 1 (S6K1). Moreover, chemical regulation of the AMPK-S6K1 pathway was found to affect Liver X receptor (LXR) activity and lipogenesis, leading to the identification of AMPK and S6K1 as targets for treating hepatic steatosis. These biological activities of dithiolethiones may offer a novel approach to pharmaceutical intervention. This review focuses on the interaction between oltipraz and the AMPK-mTOR-S6K1 pathway, which regulates genes that confer hepatocyte protection from intoxication, disrupted energy metabolism, and inflammation. In terms of therapeutic potential, the findings reviewed here demonstrate a new therapeutic potential for dithiolethiones, which function in a unique manner, and offer the possibility of new treatments for hepatic diseases.

AB - Comprehensive studies support the notion that oltipraz [4-methyl-5-(2-pyrazynyl)-1,2-dithiole-3-thione] and its congeners exert cancer chemopreventive effects by the prevention, inhibition or reversal of carcinogenic processes. Recently, it was found that dithiolethione compounds had the activities to prevent or treat fibrosis, insulin resistance, and mitochondrial protective effects in the liver by a mechanism involving AMP-activated protein kinase (AMPK) and/or 70-kDa ribosomal protein S6 kinase 1 (S6K1). Moreover, chemical regulation of the AMPK-S6K1 pathway was found to affect Liver X receptor (LXR) activity and lipogenesis, leading to the identification of AMPK and S6K1 as targets for treating hepatic steatosis. These biological activities of dithiolethiones may offer a novel approach to pharmaceutical intervention. This review focuses on the interaction between oltipraz and the AMPK-mTOR-S6K1 pathway, which regulates genes that confer hepatocyte protection from intoxication, disrupted energy metabolism, and inflammation. In terms of therapeutic potential, the findings reviewed here demonstrate a new therapeutic potential for dithiolethiones, which function in a unique manner, and offer the possibility of new treatments for hepatic diseases.

UR - http://www.scopus.com/inward/record.url?scp=68949146859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949146859&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2009.06.006

DO - 10.1016/j.pharmthera.2009.06.006

M3 - Review article

VL - 124

SP - 31

EP - 43

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1

ER -